Cargando…

Comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials

Objective: Myoclonus was considered as one conundrum in etomidate induction, which led to multiple risks during clinical anesthesia. The present study was conducted to compare the efficacy of pretreatment with remifentanil to different pharmacological approaches on reducing etomidate-induced myoclon...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Bingchen, Zhang, Lingli, Li, Fengshan, Lin, Yunzhu, Zhang, Wensheng, Yang, Chunsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512956/
https://www.ncbi.nlm.nih.gov/pubmed/31190739
http://dx.doi.org/10.2147/DDDT.S200200
_version_ 1783417712565813248
author Lang, Bingchen
Zhang, Lingli
Li, Fengshan
Lin, Yunzhu
Zhang, Wensheng
Yang, Chunsong
author_facet Lang, Bingchen
Zhang, Lingli
Li, Fengshan
Lin, Yunzhu
Zhang, Wensheng
Yang, Chunsong
author_sort Lang, Bingchen
collection PubMed
description Objective: Myoclonus was considered as one conundrum in etomidate induction, which led to multiple risks during clinical anesthesia. The present study was conducted to compare the efficacy of pretreatment with remifentanil to different pharmacological approaches on reducing etomidate-induced myoclonus. Methods: We searched PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure from the inception to October 2018. Randomized controlled trials comparing remifentanil versus other pharmacological approaches in reducing etomidate-induced myoclonus were eligible to be analyzed. Results: Overall, 13 trials with 1,392 patients met with the inclusion criteria. 1) Pretreatment with remifentanil could reduce the incidence of etomidate-induced myoclonus compared to placebo and fentanyl; few differences were found between the use of remifentanil and the use of midazolam: (incidence of myoclonus: 5.56% with remifentanil vs 71.65% with saline, RR=0.08, with 95% CI [0.05, 0.12], P<0.0001; 3.80% with remifentanil vs 13.33% with fentanyl, RR with 95% 0.31 [0.11, 0.86], P=0.02; 46.00% with remifentanil vs 55.45% with midazolam, RR=0.82, with 95% CI [0.64, 1.06], P=0.13). 2) Compared with placebo, pretreatment with remifentanil could reduce the incidence of mild, moderate, and severe myoclonus; compared with midazolam, patients receiving remifentanil experienced lower occurrence of severe myoclonus; compared with fentanyl, pretreatment with remifentanil associated with significant low occurrence of moderate and severe myoclonus. 3) The outcomes also indicated that pretreatment with remifentanil could prevent excessive hemodynamic changes after endotracheal intubation compared to fentanyl. Conclusions: Pretreatment with remifentanil could be considered as one operative option to reduce both incidence and severity of etomidate-induced myoclonus. Compared with fentanyl, it also provides efficacy in preventing excessive hemodynamic changes after endotracheal intubation. However, the best treatment and the proper prophylactic dosage calls for more high quality evidence with large sample size.
format Online
Article
Text
id pubmed-6512956
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65129562019-06-12 Comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials Lang, Bingchen Zhang, Lingli Li, Fengshan Lin, Yunzhu Zhang, Wensheng Yang, Chunsong Drug Des Devel Ther Original Research Objective: Myoclonus was considered as one conundrum in etomidate induction, which led to multiple risks during clinical anesthesia. The present study was conducted to compare the efficacy of pretreatment with remifentanil to different pharmacological approaches on reducing etomidate-induced myoclonus. Methods: We searched PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure from the inception to October 2018. Randomized controlled trials comparing remifentanil versus other pharmacological approaches in reducing etomidate-induced myoclonus were eligible to be analyzed. Results: Overall, 13 trials with 1,392 patients met with the inclusion criteria. 1) Pretreatment with remifentanil could reduce the incidence of etomidate-induced myoclonus compared to placebo and fentanyl; few differences were found between the use of remifentanil and the use of midazolam: (incidence of myoclonus: 5.56% with remifentanil vs 71.65% with saline, RR=0.08, with 95% CI [0.05, 0.12], P<0.0001; 3.80% with remifentanil vs 13.33% with fentanyl, RR with 95% 0.31 [0.11, 0.86], P=0.02; 46.00% with remifentanil vs 55.45% with midazolam, RR=0.82, with 95% CI [0.64, 1.06], P=0.13). 2) Compared with placebo, pretreatment with remifentanil could reduce the incidence of mild, moderate, and severe myoclonus; compared with midazolam, patients receiving remifentanil experienced lower occurrence of severe myoclonus; compared with fentanyl, pretreatment with remifentanil associated with significant low occurrence of moderate and severe myoclonus. 3) The outcomes also indicated that pretreatment with remifentanil could prevent excessive hemodynamic changes after endotracheal intubation compared to fentanyl. Conclusions: Pretreatment with remifentanil could be considered as one operative option to reduce both incidence and severity of etomidate-induced myoclonus. Compared with fentanyl, it also provides efficacy in preventing excessive hemodynamic changes after endotracheal intubation. However, the best treatment and the proper prophylactic dosage calls for more high quality evidence with large sample size. Dove 2019-05-09 /pmc/articles/PMC6512956/ /pubmed/31190739 http://dx.doi.org/10.2147/DDDT.S200200 Text en © 2019 Lang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lang, Bingchen
Zhang, Lingli
Li, Fengshan
Lin, Yunzhu
Zhang, Wensheng
Yang, Chunsong
Comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials
title Comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials
title_full Comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials
title_fullStr Comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials
title_full_unstemmed Comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials
title_short Comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials
title_sort comparison of the efficacy and safety of remifentanil versus different pharmacological approaches on prevention of etomidate-induced myoclonus: a meta-analysis of randomized controlled trials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512956/
https://www.ncbi.nlm.nih.gov/pubmed/31190739
http://dx.doi.org/10.2147/DDDT.S200200
work_keys_str_mv AT langbingchen comparisonoftheefficacyandsafetyofremifentanilversusdifferentpharmacologicalapproachesonpreventionofetomidateinducedmyoclonusametaanalysisofrandomizedcontrolledtrials
AT zhanglingli comparisonoftheefficacyandsafetyofremifentanilversusdifferentpharmacologicalapproachesonpreventionofetomidateinducedmyoclonusametaanalysisofrandomizedcontrolledtrials
AT lifengshan comparisonoftheefficacyandsafetyofremifentanilversusdifferentpharmacologicalapproachesonpreventionofetomidateinducedmyoclonusametaanalysisofrandomizedcontrolledtrials
AT linyunzhu comparisonoftheefficacyandsafetyofremifentanilversusdifferentpharmacologicalapproachesonpreventionofetomidateinducedmyoclonusametaanalysisofrandomizedcontrolledtrials
AT zhangwensheng comparisonoftheefficacyandsafetyofremifentanilversusdifferentpharmacologicalapproachesonpreventionofetomidateinducedmyoclonusametaanalysisofrandomizedcontrolledtrials
AT yangchunsong comparisonoftheefficacyandsafetyofremifentanilversusdifferentpharmacologicalapproachesonpreventionofetomidateinducedmyoclonusametaanalysisofrandomizedcontrolledtrials